Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status-Reference-Cited by-同舟云学术

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

Published:2019-09-01 Issue:9 Volume:76 Page:1060
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Palmqvist Sebastian¹²,Janelidze Shorena¹,Stomrud Erik¹³,Zetterberg Henrik⁴⁵⁶⁷,Karl Johann⁸,Zink Katharina⁸,Bittner Tobias⁹,Mattsson Niklas¹²,Eichenlaub Udo⁸,Blennow Kaj⁴⁵,Hansson Oskar¹³

Affiliation:

1. Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden

2. Department of Neurology, Skåne University Hospital, Malmö, Sweden

3. Memory Clinic, Skåne University Hospital, Malmö, Sweden

4. Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

5. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

6. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom

7. UK Dementia Research Institute at UCL, London, United Kingdom

8. Roche Diagnostics GmbH, Penzberg, Germany

9. Genentech, a Member of the Roche Group, Basel, Switzerland

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/article-pdf/76/9/1060/17885810/jamaneurology_palmqvist_2019_oi_190043.pdf

Reference48 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.;Albert;Alzheimers Dement,2011

2. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.;McKhann;Alzheimers Dement,2011

3. Revolutionizing Alzheimer’s disease and clinical trials through biomarkers.;Mattsson;Alzheimers Dement (Amst),2015

4. Amyloid biomarkers in Alzheimer’s disease.;Blennow;Trends Pharmacol Sci,2015

5. 2017 Alzheimer’s disease facts and figures.;Alzheimer’s Association;Alzheimers Dement,2017

Cited by 310 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An optimized UPLC-MS/MS method for human plasma amyloid-β 42 and 40 measurement and application in Alzheimer's disease diagnosis;Journal of Pharmaceutical and Biomedical Analysis;2024-11

2. Biofunctionalization-optimized MoS2-based FET biosensors for the detection of Tau protein;Applied Surface Science;2024-10

3. Alzheimer’s disease biomarkers and their current use in clinical research and practice;Molecular Psychiatry;2024-09-04

4. A streamlined, resource-efficient immunoprecipitation-mass spectrometry method for quantifying plasma amyloid-β biomarkers in Alzheimer's disease;2024-09-02

5. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment;JAMA Neurology;2024-09-01